KR20220024123A - 암의 치료에서 사용하기 위한 기능화된 금 카르벤 나프토퀴논 복합체 - Google Patents

암의 치료에서 사용하기 위한 기능화된 금 카르벤 나프토퀴논 복합체 Download PDF

Info

Publication number
KR20220024123A
KR20220024123A KR1020217041752A KR20217041752A KR20220024123A KR 20220024123 A KR20220024123 A KR 20220024123A KR 1020217041752 A KR1020217041752 A KR 1020217041752A KR 20217041752 A KR20217041752 A KR 20217041752A KR 20220024123 A KR20220024123 A KR 20220024123A
Authority
KR
South Korea
Prior art keywords
substituted
compound
alkyl
alkylamino
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217041752A
Other languages
English (en)
Korean (ko)
Inventor
조나단 엘. 세슬러
사잘 센
조나단 에프. 아람불라
정룽 추이
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20220024123A publication Critical patent/KR20220024123A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/12—Gold compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/10—Silver compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020217041752A 2019-05-22 2020-05-22 암의 치료에서 사용하기 위한 기능화된 금 카르벤 나프토퀴논 복합체 Ceased KR20220024123A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851187P 2019-05-22 2019-05-22
US62/851,187 2019-05-22
PCT/US2020/034415 WO2020237225A1 (en) 2019-05-22 2020-05-22 Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20220024123A true KR20220024123A (ko) 2022-03-03

Family

ID=73459479

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217041752A Ceased KR20220024123A (ko) 2019-05-22 2020-05-22 암의 치료에서 사용하기 위한 기능화된 금 카르벤 나프토퀴논 복합체

Country Status (11)

Country Link
US (1) US12577262B2 (https=)
EP (1) EP3972981A4 (https=)
JP (1) JP2022532801A (https=)
KR (1) KR20220024123A (https=)
CN (1) CN114174305A (https=)
AU (1) AU2020279478A1 (https=)
CA (1) CA3140716A1 (https=)
IL (1) IL288176A (https=)
MX (1) MX2021014195A (https=)
SG (1) SG11202112856QA (https=)
WO (1) WO2020237225A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201003483D0 (en) * 2010-03-02 2010-04-14 Univ St Andrews Gold complexes
US8900654B2 (en) * 2011-07-29 2014-12-02 Thin Film Electronics, Inc. Methods of polymerizing silanes and cyclosilanes using N-heterocyclic carbenes, metal complexes having N-heterocyclic carbene ligands, and lanthanide compounds
HUE033704T2 (en) 2012-02-13 2017-12-28 Bristol Myers Squibb Co Enediyne compounds, conjugates thereof, and uses and methods therefor
US20170129911A1 (en) 2015-11-10 2017-05-11 Massachusetts Institute Of Technology Complexes comprising a platinum compound and an immune checkpoint inhibitor and related methods
WO2019006327A1 (en) * 2017-06-30 2019-01-03 Board Of Regents, The University Of Texas System OR-CARBENE COMPLEXES CONTAINING NAPHTOQUINONE AND METHODS OF USE

Also Published As

Publication number Publication date
EP3972981A4 (en) 2023-05-24
CA3140716A1 (en) 2020-11-26
EP3972981A1 (en) 2022-03-30
US12577262B2 (en) 2026-03-17
AU2020279478A1 (en) 2021-12-09
CN114174305A (zh) 2022-03-11
WO2020237225A1 (en) 2020-11-26
IL288176A (en) 2022-01-01
JP2022532801A (ja) 2022-07-19
MX2021014195A (es) 2022-02-21
SG11202112856QA (en) 2021-12-30
US20220340601A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
WO2022007841A1 (zh) 一种egfr抑制剂、其制备方法和在药学上的应用
JP7082256B1 (ja) ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体
EP2854948B1 (en) Metal-based thiophene photodynamic compounds and their use
CN105940005A (zh) 二氮杂环庚烷衍生物及其用途
CN113993519A (zh) 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途
KR102412203B1 (ko) 백금 내성을 극복하는데 이용하기 위한 텍사피린-pt(iv) 접합체 및 조성물
JPH0840892A (ja) 癌細胞に対して活性を有する白金錯体
CN108368143B (zh) 用于癌症疗法的单马来酰亚胺官能化的铂化合物
CN120112532A (zh) Parg抑制性化合物
WO2022199547A1 (zh) 一种7,9-二氢嘌呤衍生物及其制药用途
WO2016124160A1 (zh) 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用
CN107556361A (zh) 裂环羽扇豆烷衍生物及其抗肿瘤用途
WO2018086242A1 (zh) pH敏感的轴向取代硅酞菁配合物及其制备方法和在医药上的应用
KR20220024123A (ko) 암의 치료에서 사용하기 위한 기능화된 금 카르벤 나프토퀴논 복합체
WO2017101862A1 (zh) 作为egfr抑制剂的5,8-二氢蝶啶-6,7-二酮衍生物及其应用
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
WO2012139487A1 (zh) 喜树碱类化合物的聚乙二醇化衍生物
US10806788B2 (en) Chlorin-vitamin conjugates
CN114057696B (zh) 一种咔唑-嘧啶衍生物及其制备方法和应用
US20230391808A1 (en) Phosphaphenalene-gold(i) complexes as chemotherapeutic agents against glioblastoma
EP4700034A1 (en) Metal complex compounds, conjugates and conjugatable compounds therefrom as well as uses thereof and processes of producing the same
CN107629063A (zh) 酸敏感的酞菁锌‑吉非替尼配合物及其制备方法和在医药上的应用
WO2023186881A1 (en) P38 map kinase inhibitors for use in the treatment of colorectal cancer
KR101713678B1 (ko) 신규 화합물 4-Ethyl-7-(2-fluoro-benzylsulfanyl)-2-methyl-1-thia-3b, 5, 6-triaza-cyclopenta[a]indene 및 이를 포함하는 항암제용 약제학적 조성물
CN120098064A (zh) 一种src-3 protac化合物及其制备方法和在治疗乳腺癌中的应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601